Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

814
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
814
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

1.1K
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
1.1K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

704
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
704

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical validation of automatic phantom-less quantitative computed tomography for osteoporosis screening: fat region of interest comparison and multidevice validation.

PloS one·2026
Same author

Development and Evaluation of a Phospholipid Complex-Loaded SMEDDS for Enhanced Oral Delivery of H007, a Novel Anti-Hyperlipidemic Drug.

Pharmaceutics·2026
Same author

Integrated Multiomic Profiling Identifies BRD8/EP400 as a Pivotal Chromatin Module Mediating Anti-HER2 Response in HR+/HER2+ Breast Cancer.

Cancer research·2026
Same author

A preclinical mouse model mimicking the ovarian cancer-induced estrogen deficiency-depression axis.

Animal models and experimental medicine·2026
Same author

Profiling of the mycobiome and metabolome: a comparative study of benign pulmonary nodules and lung adenocarcinoma.

Frontiers in cellular and infection microbiology·2026
Same author

CARM1-mediated hypoxanthine-enriched exosomes rewire inosine metabolism and impair CD8<sup>+</sup> T cell antitumor function.

Cell death and differentiation·2026

Related Experiment Video

Updated: Mar 7, 2026

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS
09:20

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

9.0K

Discovery of a Hydroxamic Acid-Based HDAC11 Isoform-Selective Inhibitor with Oral Anti-AML Potency.

Qipeng Chai1, Maoshuo Yang2, Chunxi Liu3

  • 1Department of Medicinal Chemistry, State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Key Laboratory of Chemical Biology (Ministry of Education), Shandong Key Laboratory of Druggability Optimization and Evaluation for Lead Compounds, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Ji'nan 250012, P. R. China.

Journal of Medicinal Chemistry
|March 6, 2026
PubMed
Summary

Researchers optimized compound A9 to create compound 25, a potent HDAC11 inhibitor for treating acute myeloid leukemia (AML). Compound 25 shows superior anti-AML effects and oral efficacy in mice, alone or with ivosidenib.

More Related Videos

Assays for Validating Histone Acetyltransferase Inhibitors
09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

7.1K
Examination of Proteins Bound to Nascent DNA in Mammalian Cells Using BrdU-ChIP-Slot-Western Technique
09:14

Examination of Proteins Bound to Nascent DNA in Mammalian Cells Using BrdU-ChIP-Slot-Western Technique

Published on: January 14, 2016

9.6K

Related Experiment Videos

Last Updated: Mar 7, 2026

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS
09:20

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

9.0K
Assays for Validating Histone Acetyltransferase Inhibitors
09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

7.1K
Examination of Proteins Bound to Nascent DNA in Mammalian Cells Using BrdU-ChIP-Slot-Western Technique
09:14

Examination of Proteins Bound to Nascent DNA in Mammalian Cells Using BrdU-ChIP-Slot-Western Technique

Published on: January 14, 2016

9.6K

Area of Science:

  • Medicinal Chemistry
  • Pharmacology
  • Hematology

Background:

  • Histone deacetylase 11 (HDAC11) is a validated therapeutic target for acute myeloid leukemia (AML).
  • The lead compound A9, a specific HDAC11 inhibitor, was identified in previous studies.

Purpose of the Study:

  • To develop novel, specific HDAC11 inhibitors with enhanced drug-like properties.
  • To optimize the structure of compound A9 for improved anti-AML activity.

Main Methods:

  • Structure-activity relationship (SAR) studies and synthesis of A9 derivatives.
  • In vitro assays evaluating HDAC11 inhibition, anti-AML effects, and pharmacokinetic properties.
  • In vivo studies using a mouse model of MLL-AF9-induced AML.

Main Results:

  • Compound 25 emerged as a potent and selective HDAC11 inhibitor with improved liver microsomal stability compared to A9.
  • Compound 25 demonstrated superior anti-AML efficacy over FT895, including proliferation inhibition, apoptosis induction, cell cycle arrest, differentiation promotion, and ferroptosis induction.
  • Compound 25 exhibited synergistic anti-AML effects when combined with ivosidenib and showed favorable oral pharmacokinetics and efficacy in a mouse AML model.

Conclusions:

  • Compound 25 represents a promising next-generation HDAC11 inhibitor for AML therapy.
  • The combination of compound 25 and ivosidenib offers a potent synergistic therapeutic strategy for AML.
  • Compound 25's favorable oral bioavailability supports its potential for clinical development in AML treatment.